Your session is about to expire
← Back to Search
L-methylfolate for Generalized Anxiety Disorder
Phase 4
Waitlist Available
Research Sponsored by Queen's University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Participants who do not have capacity to conduct consent process
Patients with moderate to severe major depressive disorder based on the Patient Health Questionnaire - Nine Item (PHQ-9) scale (score of 15 or above) at baseline
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-week visit and 8-week visit.
Awards & highlights
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial will test if adding L-methylfolate to the treatment of patients with treatment-resistant generalized anxiety disorder (GAD) is safe and well-tolerated. The main goal is to monitor
Who is the study for?
This trial is for individuals with Generalized Anxiety Disorder (GAD) who haven't had success with their current treatments. Participants will continue their usual GAD treatment and also take L-methylfolate.
What is being tested?
The study tests the safety and effectiveness of adding L-methylfolate to existing anxiety treatments. Patients will receive a daily dose of L-methylfolate alongside their regular medication for 8 weeks.
What are the potential side effects?
While monitoring for side effects is a primary goal, potential risks may include digestive discomfort, sleep disturbances, or allergic reactions specific to folate supplementation.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am unable to understand or sign the consent form by myself.
Select...
My depression is moderate to severe, based on a PHQ-9 score of 15 or above.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4-week visit and 8-week visit.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-week visit and 8-week visit.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of treatment-emergent adverse events
Incidence of treatment-emergent side effects measured with the ASEC
Response to treatment defined by CGI-I score below 3
Secondary study objectives
Change in anxiety severity measured by CGI-S
Change of anxiety symptoms measured with BAI
Change of anxiety symptoms measured with GAD-7
+6 moreSide effects data
From 2017 Phase 2 & 3 trial • 47 Patients • NCT0185328077%
Headache
55%
Cold/Infection/Allergy
50%
Insomnia
36%
Musculoskeletal
32%
Decreased Appetite
27%
Mucosal Dryness
27%
Tense/Jittery
27%
Nausea/Vomit/Diarrhea
18%
Anxious/worried
14%
Cardiovascular
14%
Sad/down
14%
Sedation
5%
Neurological
5%
Agitated/irritable
5%
Decreased energy
5%
Dermatological
5%
Genitourinary
100%
80%
60%
40%
20%
0%
Study treatment Arm
L-Methylfolate
Placebo (for L-Methylfolate)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: L-methylfolate armExperimental Treatment1 Intervention
Oral administration of L-methylfolate 15 mg per day for 8 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
L-methylfolate
2016
Completed Phase 3
~490
Find a Location
Who is running the clinical trial?
Queen's UniversityLead Sponsor
372 Previous Clinical Trials
123,997 Total Patients Enrolled
6 Trials studying Anxiety
596 Patients Enrolled for Anxiety
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger